My F&M

Annual Stock Picking Contest, Thom Guidi quoted in Cincinnati Business Courier

Share This Article

Thom Guidi recently spoke with Steve Watkins of the Cincinnati Business Courier about the performance of Medpace over the past year. As part of their annual stock picking contest, many experts favored the young company that provides clinical research to drug, biotech and medical device companies.

Below is an excerpt from the Cincinnati Business Courier article published on January 26:

“Medpace offers a rare mix of stability and growth,” Thom Guidi, co-chief investment officer at Kenwood-based investment advisory firm Foster & Motley, told me.

He chose it even though it’s expensive relative to its fundamentals, such as earnings and sales.

“It has over a year’s worth of backlogged contracts to fulfill and nearly no debt,” Guidi said. “Medpace’s earnings growth is largely organic. It has continued to grow its core business. And Covid interrupted its operations and sales in the second quarter but it has largely recovered since then.”

Click here to read the full article (a subscription may be required).